LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate
Portfolio Pulse from Benzinga Newsdesk
LAVA Therapeutics (NASDAQ:LVTX) reported Q4 earnings with a per-share loss of $(0.24), missing the $(0.12) estimate by 100%. Sales were $353K, significantly below the $6.25M estimate, marking a 94.35% miss and an 86.63% decrease from the previous year.
March 20, 2024 | 11:13 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
LAVA Therapeutics reported a significant miss in both EPS and sales for Q4, with EPS at $(0.24) vs. an expected $(0.12) and sales at $353K vs. an expected $6.25M.
The significant miss in both earnings per share and sales compared to analyst expectations suggests a negative short-term impact on LVTX's stock price. The magnitude of the miss, especially in sales (94.35% below estimates), indicates potential underlying issues that could concern investors, leading to decreased confidence and possibly a drop in stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100